Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that its Phase 4 study of EXPAREL® (bupivacaine liposome injectable suspension) in patients undergoing Cesarean section (C-section) achieved its primary endpoint with a statistically significant reduction in total postsurgical opioid consumption through 72 hours (P≤0.05). EXPAREL also achieved statistical significance for reduction in pain intensity scores through 72 hours (P≤0.05). The full study results will be submitted for publication in the peer-reviewed medical literature later this year.